瑞典CellaVision www.cellavision.com
CellaVision AB 開發(fā)、營(yíng)銷并銷售市場(chǎng)領(lǐng)先的用于血液和其他體液常規(guī)分析的圖像分析系統(tǒng)。公司在開發(fā)用于健康和醫(yī)療護(hù)理的細(xì)胞和細(xì)胞變化的自動(dòng)圖像分析的軟硬件領(lǐng)域具有核心競(jìng)爭(zhēng)力。它開發(fā)并營(yíng)銷白細(xì)胞和紅細(xì)胞的自動(dòng)分類系統(tǒng)，以及分類的教學(xué)和質(zhì)量保證軟件。公司的合作者擁有高級(jí)圖像分析、人工智能和自動(dòng)顯微鏡學(xué)的專業(yè)技術(shù)。
公司總部位于瑞典的隆德（Lund），在美國(guó)佛羅里達(dá)，加拿大多倫多和日本的橫濱都有分支機(jī)構(gòu)。

CellaVision AB develops and markets products for the health care sector, enabling fast and firm blood cell analysis and quality assurance of morphology diagnosis.
The company has cutting-edge expertise within sophisticated digital image analysis, artificial intelligence and automated microscopy. For laboratories, this means increased efficiency, a simplification of the procedures and confirmed proficiency.
 

The product line includes systems for automatic blood cell differentials and software for differential proficiency testing and education. The products are sold to hospital laboratories and independent commercial laboratories. Today CellaVision is represented in Europe, the U.S. and to some extent in Asia.
Vision 
To create a global de facto standard for digital microscopy analysis and thereby contribute to improved care quality and cost efficient medical care

Background
Based in Lund, Sweden, CellaVision was founded in 1994. The CellaVision concept of automated microscopy analysis comes from Christer Fåhraeus and engineers connected to Lund Institute of Technology and the Ideon Science Park. Since 2001, the company also has a U.S. subsidiary in Jupiter, Fl, USA. In January 2007, a subsidiary in Toronto, ON, Canada was established, and one year later a subsidiary in Yokohama, Japan.
Owners
CellaVision has about 700 shareholders who have provided capital in connection with new stock issues. The principal owner is H&B Capital LP. Other major shareholders are Stiftelsen Industrifonden, Metallica Förvaltnings AB, Christer Fåhraeus, Life Equity Sweden KB and SIF.